Anti-human Tim-3 monoclonal antibody and preparation method thereof

Through flow cell sorting and single-cell antibody library building technology, anti-human Tim-3 monoclonal antibodies were developed, solving the problems of low development efficiency and poor antibody specificity in the existing technology, and achieving rapid and efficient antibodies Development and high-throughput production for the detection of Tim-3 protein.

CN118373913BActive Publication Date: 2024-11-01BIOINTRON BIOLOGICAL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410561740.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-08
Publication Date
2024-11-01
Estimated Expiration
2044-05-08

AI Technical Summary

Technical Problem

The prior art has problems such as time-consuming, low efficiency, susceptibility to cell fusion and poor antibody specificity and affinity in the development of anti-human Tim-3 monoclonal antibodies, especially in hybridoma technology and phage display technology.

Method used

Using single B cells as the research subject, mouse B cells expressing positive antibodies were sorted by flow cytometry, using single-cell antibody library library building method to maintain the natural pairing of light and heavy chains of the antibody, and combining with a high-throughput expression system to achieve antibody Rapid development and verification.

Benefits of technology

It shortens the time for antibody development, improves throughput and positivity rate, ensures antigen-antibody binding activity, and is suitable for ELISA and FACS detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118373913B_ABST
    Figure CN118373913B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of molecular biology technology, and specifically relates to an anti-human Tim‑3 monoclonal antibody and a preparation method thereof. The anti-human Tim‑3 monoclonal antibody of the present invention comprises VHCDR1, VHCDR2 and VHCDR3 as shown in SEQ ID NO: 1‑3 as an amino acid sequence; and VLCDR1, VLCDR2 and VLCDR3 as shown in SEQ ID NO: 4‑6 as an amino acid sequence. The antibody development process of the present invention is as follows: Human Tim‑3 / His Protein is expressed, and mice are rapidly immunized in combination with water-soluble adjuvants, and mouse spleen and bone marrow cells are collected; mouse B cells that bind to Human Tim‑3 antigen are screened using a flow sorter; single-cell libraries are constructed for positive B cells, and antibody sequences of natural pairing of light and heavy chains are obtained by NGS sequencing; after further screening the sequence, the antibody is expressed by a mammalian cell high-throughput expression system; and finally, the antibody is verified by antibody detection. The monoclonal antibody of the present invention has good antigen-antibody binding activity at both the molecular and cellular levels.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of molecular biology, and specifically relates to an anti-human Tim-3 monoclonal antibody and a preparation method thereof. Background Art

[0002] Tim-3 (T cell immunoglobulin and mucin domain 3) belongs to the immunoglobulin superfamily. It is a molecule expressed on the surface of a variety of immune cells, including type I cell surface glycoproteins of T cells, B cells, dendritic cells and natural killer cells, and is involved in cell apoptosis. Tim-3 is an immunostimulatory molecule and an immunosuppressive molecule, depending on the different cells expressing the Tim-3 receptor and the tumor microenvironment. Under normal circumstances, Tim-3 is involved in maintaining immune balance, regulating the activity of T cells, and preventing overactivation and inflammatory response. However, in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), the expression level of Tim-3 may be abnormally increased. This increase is related to the abnormal function of T cells, which may lead to the continuous activation of T cells and the production of a large number of inflammatory mediators, thereby initiating and aggravating the inflammatory response. In the tumor microenvironment, the high expression of Tim-3 is associated with the inhibition of T cell function, which makes T cells lose the ability to recognize and kill tumor cells and promotes the immune escape of tumors. In order to overcome this immunosuppression, researchers are exploring ways to enhance the killing ability of T cells against tumors by blocking the Tim-3 signaling pathway. For example, the use of anti-Tim-3 antibodies can prevent it from binding to ligands, thereby restoring the function of T cells and improving the efficacy of tumor immunotherapy. In addition, using gene editing technology to make T cells express Tim-3 mutants that do not have immunosuppressive function is also a possible strategy. In clinical trials, immunotherapy strategies targeting Tim-3 have shown certain potential, especially when used in combination with other immune checkpoint inhibitors such as PD-1 / PD-L1 inhibitors, which may produce more synergistic effects. Therefore, the development of anti-human Tim-3 monoclonal antibodies has good application prospects.

[0003] Hybridoma technology is currently the most mature and widely used monoclonal antibody development platform, but it is time-consuming, has low cell fusion efficiency, and is limited in the species it can be applied to. Although phage display technology shortens the antibody development time, it affects the specificity and affinity of the antibody because it cannot ensure the natural pairing of light and heavy chains. Summary of the invention

[0004] In view of the common defects of the prior art, the present invention provides an anti-human Tim-3 monoclonal antibody and a preparation method thereof. The monoclonal antibody development method provided by the present invention has the advantages of short time consumption, high throughput, high positive rate, etc., and has good antigen-antibody binding activity at both the molecular and cellular levels, providing support for ELISA, FACS and other detection of human Tim-3 protein.

[0005] The present invention uses single B cells as the research subject, uses flow cytometry to sort out mouse B cells expressing positive antibodies, and adopts a single-cell antibody library construction method to maintain the natural pairing of antibody light and heavy chains, replacing the hybridoma cell fusion and culture that is inefficient, time-consuming, and susceptible to contamination.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0007] In the first aspect of the present invention, an anti-human Tim-3 monoclonal antibody is provided, which comprises VHCDR1, VHCDR2 and VHCDR3 whose amino acid sequences are shown in SEQ ID NOs: 1-3; and VLCDR1, VLCDR2 and VLCDR3 whose amino acid sequences are shown in SEQ ID NOs: 4-6.

[0008] Furthermore, the antibody comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:7.

[0009] Furthermore, the antibody comprises a light chain variable region having an amino acid sequence as shown in SEQ ID NO:8.

[0010] In the second aspect of the present invention, a method for preparing an anti-human Tim-3 monoclonal antibody as described in the first aspect is also provided, and the process is as follows: Human Tim-3 / His Protein is expressed, and mice are rapidly immunized in combination with a water-soluble adjuvant, and mouse spleen and bone marrow cells are collected; mouse B cells that bind to the Human Tim-3 antigen are screened using a flow cytometer; single-cell libraries are constructed for positive B cells, and antibody sequences with natural pairing of light and heavy chains are obtained by NGS sequencing; after further screening the sequences, the antibodies are expressed by a mammalian cell high-throughput expression system; and finally, the results are verified by ELISA and FACS detection.

[0011] Specifically, the preparation method comprises the following steps:

[0012] S1. Express Human Tim-3 / His Protein based on the protein sequence information of Human Tim-3;

[0013] S2, using the Human Tim-3 / His Protein obtained in step S1 in combination with a water-soluble adjuvant to rapidly immunize mice, and then extracting spleen and bone marrow cells from the mice;

[0014] S3, using the mouse cells obtained in step S2 as raw materials, screening cells expressing positive antibodies by flow cytometry, constructing an antibody library through a single-cell library construction system, and performing next-generation sequencing;

[0015] S4, screening the antibody sequences obtained in step S3, extracting antibody sequences of natural pairing of light and heavy chains, and cloning them into vector pcDNA3.4;

[0016] S5. Induce high-throughput expression of anti-Human Tim-3 antibody through mammalian cell high-throughput expression system, verify antigen binding through antibody detection technology ELISA and FACS method, and finally obtain anti-Human Tim-3 monoclonal antibody.

[0017] In the third aspect of the present invention, a nucleic acid encoding the anti-human Tim-3 monoclonal antibody as described in the first aspect is also provided.

[0018] In the fourth aspect of the present invention, an expression vector containing the nucleic acid as described in the third aspect is also provided, and preferably the expression vector is pcDNA3.4.

[0019] In the fifth aspect of the present invention, a host cell containing the expression vector as described in the fourth aspect is also provided, and preferably the host cell is a CHO cell.

[0020] In the sixth aspect of the present invention, there is also provided the use of the anti-human Tim-3 monoclonal antibody as described in the first aspect in the preparation of a human Tim-3 protein detection reagent.

[0021] In the seventh aspect of the present invention, there is also provided the use of the anti-human Tim-3 monoclonal antibody as described in the first aspect in the preparation of a product binding to human Tim-3 protein.

[0022] Compared with the prior art, the technical effects of the present invention are as follows: the development method of the anti-Human Tim-3 monoclonal antibody provided by the present invention shortens the development time of the target antibody, and has high throughput and high positive rate, and has good antigen-antibody binding activity at both the molecular and cellular levels. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The results of mouse serum titer detection at different dilutions.

[0024] Figure 2 The results of flow cytometry.

[0025] Figure 3 Antigen binding test results.

[0026] Figure 4 Results of cell binding assay. DETAILED DESCRIPTION

[0027] The present invention is further described in detail below with reference to the examples. However, the present invention is not limited to the examples given. The methods used are conventional methods unless otherwise specified, and the reagents and materials used are commercially available unless otherwise specified.

[0028]

[0029]

[0030] Example 1

[0031] The method for developing the anti-Human Tim-3 monoclonal antibody of the present invention comprises the following steps:

[0032] S1. Based on the protein sequence and gene sequence information of Human Tim-3 (Genbank: AAH63431.1), the antigen was expressed and a His-tag was connected to its C-terminus to obtain a modified Human Tim-3 / His protein for subsequent mouse immunization.

[0033] S2. Human Tim-3 / His protein was fluorescently labeled with Alexa Fluor 488 using the Alexa Fluor 488 antibody labeling kit for subsequent mouse cell screening.

[0034] S3. Construction of CHOK1-hTim-3 cell overexpression cell line: synthesize pLVX-IRES-puro-hTim3 plasmid by gene recombination, dilute psPAX2 plasmid, PMD2G plasmid and pLVX-IRES-puro-hTim3 plasmid into culture medium, add PEI and incubate at room temperature for 15 min; add the above mixture to 293T cells, collect the supernatant of lentiviral particles after 72 hours, and filter with a 0.45 μM filter; inoculate the lentiviral particles into CHO-K1 cells, and add 1 / 100 volume of F108 infection enhancement solution, discard and replace with fresh culture medium after 6-8 hours, expand culture after 48 hours, and add 10 μg / mL puromycin for resistance screening. The cells that can continue to grow and be passaged are CHOK1-hTim3 cells.

[0035] S4. Rapidly immunize mice with the Human Tim-3 / His protein obtained in step S1 and a water-soluble adjuvant: dilute the Human Tim-3 / His protein with a water-soluble adjuvant, and inject it intraperitoneally and subcutaneously into mice for primary immunization. On the 10th day, perform a second immunization with the Human Tim-3 / His protein, and collect blood for Anti-Human Tim-3 / His serum titer 3 days later; after the serum titer is qualified, collect the spleen and bone marrow cells of the mice for screening.

[0036] The titer of Anti-Human Tim-3 / His Protein serum was detected by ELISA. The detection process was as follows: the ELISA plate was coated with 2μg / mL Human Tim-3 / His protein and incubated at 37℃ for 2h; washed with 0.05% PBST and blocked with 1% BSA at room temperature for 2h; washed with 0.05% PBST, and 3-fold gradient dilutions of mouse sera before and after immunization were added, with the first two wells being 100 and 1000 times diluted, and incubated at room temperature for 1h; washed with 0.05% PBST, and Anti-mouse IgG (Fc specific) HRP was added, and incubated at room temperature for 30min; washed with 0.05% PBST, and Bio-Tech TMB colorimetric solution was added, and reacted at room temperature for 10min, and then Bio-Tech TMB stop solution was added to immediately stop the reaction, and OD450 was read immediately. The results are as follows Figure 1 As shown in the figure, the titer of the antiserum after 2 immunizations was 81,000. This shows that the antigen can induce mice to produce high-titer antiserum specific for Human Tim-3 / His Protein.

[0037] S5. Collect spleen and bone marrow cells from immunized mice, centrifuge at 400g for 5 min, resuspend in 1mL red blood cell lysis buffer, stop red blood cell lysis with a large volume of Macs buffer, centrifuge at 400g for 5 min, resuspend in 1mL Macs buffer, add AF488-HumanTim-3 / His protein and fluorescent antibodies for B cell-specific molecular markers, incubate at 4℃ for 1h, resuspend in a large volume of Macs buffer, centrifuge at 400g for 5 min, discard the supernatant, resuspend the cells in buffer, and sort the positive cells using a flow cytometer. The results are shown in Figure 2 As shown, the antigen-positive ratio was approximately 1.02%.

[0038] S6. The positive mouse cells obtained by sorting were constructed using the single-cell library construction platform, and the constructed library was sequenced by the second generation. The antibodies with natural pairing of light and heavy chains were obtained through data analysis. 12 antibody sequences were randomly selected and recombined into the pcDNA3.4 expression vector, and transfected into the CHO-K1 cell line. Finally, 12 antibodies were expressed, namely Ab1~Ab12.

[0039] S7. ELISA was used to detect the antigen binding activity of 12 antibodies. The specific steps were as follows: the ELISA plate was coated with 2 μg / mL Human Tim-3 / His protein at 4°C overnight; washed with 0.05% PBST and blocked with 1% BSA at room temperature for 2 h; washed with 0.05% PBST, 12 antibodies, positive control and isotype control were added in 5-fold gradient dilutions, respectively, and incubated at room temperature for 1 h; washed with 0.05% PBST, Anti-human IgG (Fc specific) HRP was added, and incubated at room temperature for 30 min; washed with 0.05% PBST, TMB colorimetric solution was added, and the reaction was allowed to react at room temperature for 10 min, and then TMB stop solution was added to stop the reaction immediately, and the OD450 was read immediately. Figure 3 The results showed that the positive rate of the 12 antibodies was 100% (12 / 12), among which the EC50 of Ab1, Ab2, Ab4, Ab5, Ab6, and Ab7 were lower than that of the positive reference Anti-Human Tim-3 antibody (Sabatolimab), which were 0.2170nM, 0.2516nM, 0.2417nM, 0.2500nM, 0.2379nM, and 0.2145nM, respectively.

[0040] S8. Flow cytometry was used to detect the cell binding activity of 12 antibodies. The specific steps were as follows: 1E5 CHOK1-hTim-3 cells were inoculated in each well of a 96-well plate, centrifuged at 400 g for 5 min, 50 μL of 5-fold gradient diluted antibodies were added to each well, incubated at 4°C for 1 h, washed 3 times, 100 μL of diluted Goat anti-Human IgG Alexa Fluor 647 was added to each well, incubated at 4°C for 30 min, washed 5 times, resuspended in 200 μL 1× PBS, and detected by flow cytometry. Figure 4 As a result, the positive rate of 12 antibodies was 58.33% (7 / 12), among which the EC50 of Ab6 was lower than that of the positive reference Anti-Human Tim-3 antibody (Sabatolimab), which was 0.5691nM. Therefore, the anti-Tim-3 monoclonal antibody numbered Ab6 has both antigen and cell binding activity and shows higher binding activity than the positive reference.

[0041] The sequence of the anti-Tim-3 monoclonal antibody numbered Ab6 is shown in the following table:

[0042] type Sequence number VHCDR1 SEQ ID NO:1 VHCDR2 SEQ ID NO:2 VHCDR3 SEQ ID NO:3 VLCDR1 SEQ ID NO:4 VLCDR2 SEQ ID NO:5 VLCDR3 SEQ ID NO:6 VH SEQ ID NO:7 V L SEQ ID NO:8

[0043] The above are only embodiments of the present invention, and are not intended to limit the patent scope of the present invention. Any equivalent transformations made using the contents of the present invention specification, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. An anti-human Tim-3 monoclonal antibody, characterized in that: The monoclonal antibody comprises VHCDR1, VHCDR2 and VHCDR3 whose amino acid sequences are shown in SEQ ID NOs: 1-3; and VLCDR1, VLCDR2 and VLCDR3 whose amino acid sequences are shown in SEQ ID NOs: 4-6.

2. The anti-human Tim-3 monoclonal antibody according to claim 1, characterized in that The antibody comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:

7.

3. The anti-human Tim-3 monoclonal antibody according to claim 1, characterized in that The antibody comprises a light chain variable region having an amino acid sequence as shown in SEQ ID NO:

8.

4. A nucleic acid encoding the anti-human Tim-3 monoclonal antibody according to any one of claims 1 to 3.

5. An expression vector containing the nucleic acid according to claim 4.

6. A host cell containing the expression vector according to claim 5.

7. Use of the anti-human Tim-3 monoclonal antibody according to any one of claims 1 to 3 in the preparation of a human Tim-3 protein detection reagent.

8. Use of the anti-human Tim-3 monoclonal antibody according to any one of claims 1 to 3 in the preparation of a product that binds to human Tim-3 protein.